Skip to main content

Global Companion Diagnostics Market Is Projected to Reach $7,536.7 Million by 2030

 

As depicted, the genome sequencing cost is decreasing while the production (TB) is increasing. It is expected that the cost of genome sequencing would ultimately drop to as low as $100 by 2025. As a result, it is highly possible that the use of genome sequencing will become more widely adopted and integrated into regular clinical practice, thereby bolstering the scope of companion diagnostic usage across the healthcare continuum for treatment preferences.

As per BIS Research analysis, the global companion diagnostics market is projected to reach $7,536.7 million by 2030 from $1,764.7 million in 2019, at a CAGR of 12.45% during the forecast period of 2020-2030. This growth has been primarily attributed to the major drivers in this market, which comprise the growing incidence of cancer within the global population that has intensified the demand for better treatment assurance for all cancer types. Additionally, the growing demand for personalized medicine and the regulatory mandate for the co-development of drugs and diagnostics are driving the growth of the global CDx market. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include the development of multiple-biomarker based CDx, powered by NGS technology, commercialization of CDx for non-oncology disease areas, and exploitation of advance data science technology in the field of companion diagnostics. However, there are significant challenges which are restraining the market growth. These challenges include an uncertain reimbursement scenario, companion diagnostics leakage in oncology and weak synchronization between therapeutics and diagnostics in marketing and distribution channels.

The BIS Research report on the global companion diagnostics market segments the market on the basis of technology (in-situ hybridization, immunohistochemistry, polymerase chain reaction, and next-generation sequencing), application area (lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, stomach cancer, and others), and region (North America, Europe, Asia-Pacific, and Rest-of-the-World).

Comments

Popular posts from this blog

Liquid Biopsy, North America, and Lung Cancer Occupying a Major Share in the Market

  Owing to the market availability of large number of liquid biopsy technologies, the liquid biopsy segment currently accounts for a dominating share in the global minimally invasive biopsy technologies market . However, the market growth in the segment can be attributed to the increasing demand for liquid biopsy and the strong product pipeline. For instance, CNI Second Opinion by Chronix Biomedical is presently under development and is expected to get launched during the forecast period 2019-2030. Owing to a widespread market presence of leading players and the huge prevalence of cancer, North America presently holds a major share in the global minimally invasive biopsy technologies market. According to the World Cancer Research Fund (WCRF), with an estimated 2 million cases in 2018, lung cancer is the most commonly occurring cancer in men and third-most commonly occurring cancer in women. Due to the widespread presence of cancer, the manufacturers including Biocept, Inc., Chron...

Personal Care Ingredients Market Size, Share & Trends Analysis Report 2019-2029

The introduction and proliferation of bio-based ingredients in several industries, such as food and beverage, pharmaceuticals, and cosmetics, has been transforming the manufacturing landscape since 2000. Growing consumer inclination toward the adoption of bio-based products due to rising health and environmental concerns is driving the demand for bio-based ingredients in the cosmetics and personal care products. Besides, awareness among consumers regarding the harmful effects of synthetic ingredients chemicals has grown rapidly over the past years. In addition, the availability of green raw materials has also urged large cosmetic firms to develop bio-based cosmetic products. However, limited availability of raw material, due to erratic weather conditions and stringent environmental regulations, can pose substantial hurdles in the production of bio-based ingredients. Thus, leading companies have been focusing on developing new and sustainable ways of producing the ingredi...

ADAS and Autonomous Driving Component Market

As per the recent BIS Research report, the ADAS and autonomous driving component market is segmented into component type, level of autonomy, vehicle type, and region for the purpose of study. These segments are further sub-segmented into various categories. In case of market by component type, it is sub-segmented into camera, radar, ultrasonic sensors, LiDAR, and ECU. The use of LiDAR is increasing rapidly in the market owing to reducing cost of LiDAR sensors and their greater range.